cine,
David Geffen School of Medicine at the University of California at Los
Angeles and the lead clinical investigator, "For the patients in this
study, adjunctive use of nebulized formoterol fumarate and tiotropium
showed statistically significant improvements in lung function by improving
bronchodilation over use of tiotropium alone. For physicians,
Perforomist(TM) Inhalation Solution and commonly prescribed long-acting
anticholinergics such as tiotropium offers a new and valuable treatment
option for COPD patients with moderate to severe manifestations of the
disease."
Christy Taylor, Chief Operating Officer at Dey, L.P., commented, "At
DEY, we specialize in developing effective new treatments for serious and
complex respiratory diseases, and it is gratifying that the newest addition
to our franchise, Perforomist(TM) Inhalation Solution, offers physicians
additional prescribing flexibility. For over a decade, Dey, L.P. has been
the U.S. leader in sales of nebulized respiratory medication. We thank Dr.
Tashkin and the other members of the research team for their assessment of
how Perforomist(TM) Inhalation Solution may be used concomitantly with
tiotropium for improved clinical effect for COPD patients."
For those attending CHEST 2007, the presentation is available as follows:
Poster viewing: Session ID 902 -- COPD Treatment II
Wednesday, October 24, 2007, 12:30 -- 2:00 PM
Convention Center, Exhibit Hall, McCormick Place, Lakeside Center,
Chicago.
Poster # 251: Safety and Efficacy of Concomitant Treatment with Nebulized
Formoterol and Tiotropium in COPD
The research presented at CHEST 2007 was supported through grants
provided by Dey, L.P., which developed and markets Perforomist(TM)
Inhalation Solution. Dey, L.P. is a subsidiary of Mylan Inc. (NYSE:
SOURCE Dey, L.P. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine technology :1.
Genetic Analysis Systems Enter the Clinical Mainstream2.
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs3.
Large Geographic Differences in EpiPen Prescriptions in the U.S.,
From the Journal of Allergy and Clinical Immunology4.
Sygnis Pharma AG announces date for presentation of clinical
results5.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis6.
Clinical Data Suggest Decreased Bleeding Risk in People With Severe
Hemophilia A While Maintaining Factor VIII Levels Above One Percent7.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis8.
Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society9.
Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease10.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease11.
Protox Announces Positive Clinical Data from Prostate Cancer Study